Only auristatin PE
(TZT-1027 or soblidotin) (54; Scheme 12) is still in clinical
trials as the base molecule, and there are some very
interesting modifications that have been made by medicinal
chemists in order to deliver this close relative to dolastatin10
by use of monoclonal antibodies targeted at specific
epitopes